Fig. 3.

Lethality from blast injury is significantly reduced by the administration of the hemostatic nanoparticles. (A) Administration of the hemostatic nanoparticles increased survival at 1 h to 95% (n = 21), compared with 60% survival with no treatment (n = 10) (OR, 13; 95% CI, 1.2–143). There was no significant difference between any other groups. (B) A small group of animals that survived to 1 h were maintained to 1 wk and 3 wk. The majority of these animals survived without any apparent complications from treatment. Lethality differences were not statistically significant (1 wk, P = 0.476; 3 wk, P = 0.387).